

10-02-06

Receipt

CASE ON/4-32326A



FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV67811310345

Express Mail Label Number

September 29, 2006

Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

HEIKKI JOENSUU

APPLICATION NO: 10/502,534

FILED: JANUARY 5, 2005

FOR: TREATMENT OF RHEUMATOID ARTHRITIS USING IMATINIB

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

LETTER CORRECTING OFFICIAL FILING RECEIPT

Sir:

The official filing receipt received in the above-identified application erroneously lists the title. The transmittal letter sent to the PTO on July 26, 2004, filing the application in the national stage, listed the title correctly. The title has been established by the International Searching Authority to read as follows: "TREATMENT OF RHEUMATOID ARTHRITIS USING IMATINIB". Please see first sheet of Form PCT/ISA210 (a copy of which is enclosed herewith). Accordingly, please issue a corrected filing receipt listing the title as follows:

-- TREATMENT OF RHEUMATOID ARTHRITIS USING IMATINIB --

A copy of the filing receipt with the correction noted is enclosed.

No fee is believed to be required by this request for a corrected filing receipt.

Respectfully submitted,

Oona A. Jackson
Attorney for Applicant
Reg. No. 48,152

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-7852
Date: Sept. 29/2006



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/502,534	01/05/2005	1614	1222	ON/4-32326A		20	5

001095
NOVARTIS
CORPORATE INTELLECTUAL PROPERTY
ONE HEALTH PLAZA 104/3
EAST HANOVER, NJ 07936-1080



CONFIRMATION NO. 7483

FILING RECEIPT



OC000000019889160

Date Mailed: 08/07/2006

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please mail to the Commissioner for Patents P.O. Box 1450 Alexandria Va 22313-1450. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Heikki Joensuu, Espoo, FINLAND;

Power of Attorney: The patent practitioners associated with Customer Number 1095.

Domestic Priority data as claimed by applicant

This application is a 371 of PCT/EP03/00802 01/27/2003

Foreign Applications

UNITED KINGDOM 0201882.8 01/28/2002

Projected Publication Date: 11/09/2006

Non-Publication Request: No

Early Publication Request: No



Title

Treatment of rheumatoid arthritis using Imatinib

Preliminary Class

514

PATENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference 4-32326A	FOR FURTHER ACTION see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No. PCT/ EP 03/ 00802	International filing date (day/month/year) 27/01/2003	(Earliest) Priority Date (day/month/year) 28/01/2002
Applicant HYKS-INSTITUUTTI OY		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 6 sheets.

☒ It is also accompanied by a copy of each prior art document cited in this report.

1. Basis of the report

- a. With regard to the language, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

☐ the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

- b. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of the sequence listing:

☐ contained in the international application in written form.

☐ filed together with the international application in computer readable form.

☐ furnished subsequently to this Authority in written form.

☐ furnished subsequently to this Authority in computer readable form.

☐ the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

☐ the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2. ☒ Certain claims were found unsearchable (See Box I).

3. ☐ Unity of invention is lacking (see Box II).

4. With regard to the title,

☐ the text is approved as submitted by the applicant.

☒ the text has been established by this Authority to read as follows:

TREATMENT OF RHEUMATOID ARTHRITIS USING IMATINIB

5. With regard to the abstract,

☒ the text is approved as submitted by the applicant.

☐ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the drawings to be published with the abstract is Figure No.

☐ as suggested by the applicant.

☐ because the applicant failed to suggest a figure.

☐ because this figure better characterizes the invention.

☐ None of the figures.